AVIR
Price
$2.99
Change
+$0.06 (+2.05%)
Updated
Mar 31 closing price
Capitalization
250.59M
36 days until earnings call
PGEN
Price
$1.48
Change
-$0.01 (-0.67%)
Updated
Apr 1, 12:05 PM (EDT)
Capitalization
467.53M
36 days until earnings call
Ad is loading...

AVIR vs PGEN

Header iconAVIR vs PGEN Comparison
Open Charts AVIR vs PGENBanner chart's image
Atea Pharmaceuticals
Price$2.99
Change+$0.06 (+2.05%)
Volume$240.65K
Capitalization250.59M
Precigen
Price$1.48
Change-$0.01 (-0.67%)
Volume$3.51K
Capitalization467.53M
AVIR vs PGEN Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. PGEN commentary
Apr 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and PGEN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 01, 2025
Stock price -- (AVIR: $2.99 vs. PGEN: $1.49)
Brand notoriety: AVIR and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 80% vs. PGEN: 104%
Market capitalization -- AVIR: $250.59M vs. PGEN: $467.53M
AVIR [@Biotechnology] is valued at $250.59M. PGEN’s [@Biotechnology] market capitalization is $467.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, both AVIR and PGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 4 TA indicator(s) are bullish while PGEN’s TA Score has 3 bullish TA indicator(s).

  • AVIR’s TA Score: 4 bullish, 5 bearish.
  • PGEN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AVIR is a better buy in the short-term than PGEN.

Price Growth

AVIR (@Biotechnology) experienced а -6.56% price change this week, while PGEN (@Biotechnology) price change was -18.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.59%. For the same industry, the average monthly price growth was -10.76%, and the average quarterly price growth was -10.15%.

Reported Earning Dates

AVIR is expected to report earnings on May 07, 2025.

PGEN is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-8.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PGEN($468M) has a higher market cap than AVIR($251M). PGEN YTD gains are higher at: 33.036 vs. AVIR (-10.746). PGEN has higher annual earnings (EBITDA): -136.11M vs. AVIR (-192.53M). AVIR has more cash in the bank: 455M vs. PGEN (28.6M). AVIR has less debt than PGEN: AVIR (1.64M) vs PGEN (5.75M). PGEN has higher revenues than AVIR: PGEN (3.96M) vs AVIR (0).
AVIRPGENAVIR / PGEN
Capitalization251M468M54%
EBITDA-192.53M-136.11M141%
Gain YTD-10.74633.036-33%
P/E RatioN/AN/A-
Revenue03.96M-
Total Cash455M28.6M1,591%
Total Debt1.64M5.75M29%
FUNDAMENTALS RATINGS
AVIR vs PGEN: Fundamental Ratings
AVIR
PGEN
OUTLOOK RATING
1..100
862
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
7836
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (45) in the Biotechnology industry is in the same range as PGEN (75) in the null industry. This means that AVIR’s stock grew similarly to PGEN’s over the last 12 months.

AVIR's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that AVIR’s stock grew similarly to PGEN’s over the last 12 months.

AVIR's SMR Rating (96) in the Biotechnology industry is in the same range as PGEN (99) in the null industry. This means that AVIR’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (36) in the null industry is somewhat better than the same rating for AVIR (78) in the Biotechnology industry. This means that PGEN’s stock grew somewhat faster than AVIR’s over the last 12 months.

AVIR's P/E Growth Rating (95) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that AVIR’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRPGEN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 7 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
77%
Bullish Trend 9 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
80%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Ad is loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JIHCX17.210.12
+0.70%
JPMorgan International Hedged Equity C
AMKIX11.54N/A
N/A
American Century Emerging Markets I
GTCIX17.13N/A
N/A
Glenmede Disciplined International EqPtf
JGINX65.72N/A
N/A
Janus Henderson Growth And Income I
GWEZX30.85N/A
N/A
AMG GW&K Small Cap Core Z

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with FHTX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then FHTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+2.05%
FHTX - AVIR
48%
Loosely correlated
+3.69%
HEPA - AVIR
47%
Loosely correlated
-10.44%
AXON - AVIR
46%
Loosely correlated
-1.68%
IMNM - AVIR
46%
Loosely correlated
-3.72%
KALV - AVIR
44%
Loosely correlated
-3.27%
More